0001628280-26-029323
SEC filingDelaware Court invalidated Context Therapeutics' staggered board and for-cause removal provisions, case dismissed after third-party payment of $850,000 mootness fee, resolving stockholder action.
The resolution of the stockholder class action eliminates prior restrictions on director elections and removals by invalidating the staggered board structure and for-cause removal requirement in the Charter. This change, effectuated via court-approved Stipulated Judgment and Certificate of Correction, shifts the Company to annual director elections without cause removal barriers, potentially increasing stockholder influence on board composition at the June 24, 2026 annual meeting. The $850,000 Mootness Fee, covering plaintiff's counsel fees and expenses, was fully covered by a third-party Provider under the Letter Agreement, avoiding direct Company cash outflow. The Court's retention of jurisdiction ensures closure post-meeting quorum confirmation, providing finality to the matter.